<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440622</url>
  </required_header>
  <id_info>
    <org_study_id>CT/03.09</org_study_id>
    <nct_id>NCT00440622</nct_id>
  </id_info>
  <brief_title>Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients</brief_title>
  <official_title>A Multicenter Randomized Phase III Study of Gemcitabine Plus Herceptin Combination Versus the Capecitabine Plus Herceptin Combination in Pretreated Patients With HER-2 Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal treatment for pretreated patients with metastatic breast cancer has not been
      established. Gemcitabine and capecitabine are two active agents in this setting. For women
      with Her-2 positive breast cancer, combinations of either gemcitabine or capecitabine
      (Xeloda) plus Herceptin has been proved active and well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial compares the efficacy of the combinations gemcitabine plus Herceptin versus
      capecitabine (Xeloda) plus Herceptin in pretreated patients with metastatic HER-2 positive
      breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to poor accrual
  </why_stopped>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP) between the two treatment arms</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>During the time of chemotherpy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GHer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CapHer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine (Xeloda)</intervention_name>
    <description>Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior
             chemotherapy received

          -  HER-2 overexpression 2+ or 3+ using IHC or FISH +

          -  Measurable disease

          -  At least one prior chemotherapy regimen

          -  Not in a prior irradiation field

          -  No patients with brain metastatic disease who has not been irradiated or uncontrolled
             brain metastatic disease after irradiation

          -  No more than 25% of myeloproductive bone marrow irradiated. More than 4 weeks since
             prior radiotherapy and recovered

          -  Age 18 - 75 year old

          -  Performance status (WHO) 0-2

          -  Life expectancy more than 12 weeks

          -  Absolute neutrophil count &gt; 1500/mm^3, platelet count &gt; 100000/mm^3, hemoglobin &gt; 9
             gr/mm^3)

          -  Adequate liver (bilirubin &lt; 2 mg/dL, SGOT/SGPT &lt; 2 times upper limit of normal, ALP &lt;
             3 times upper limit of normal, creatinine &lt; 1.5 upper limit of normal

          -  Adequate cardiac function (LVEF &gt; 50%)

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Positive pregnancy test

          -  Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce
             P-450 cytochrome

          -  Motor or sensory neuropathy &gt; grade 1 according to NCIC toxicity criteria

          -  History of allergic reaction attributed to docetaxel

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Other concurrent uncontrolled illness

          -  Other invasive malignancy within the past 5 years except cured basal cell skin
             carcinoma and cervical carcinoma in situ
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Mavrudis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Marika Iliadis&quot; Hospital of Athens, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State General Hospital of Larissa, Dep of Medical Oncology</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Metastatic Breast cancer</keyword>
  <keyword>Her-2 expression</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Herceptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

